|
July 2024 IGOR KORALNIK, MD, AND SHERRY CHOU, MD, JOIN THE BIOVIE ADVISORY BOARD FOR BEZISTERIM IN LONG COVIDBioVie Inc., a clinical stage company developing drug therapies for neurological and neurodegenerative disorders and advanced liver disease, recently announced the formation of a long COVID advisory board that will provide strategic guidance on the design and execution of a phase 2b trial in patients with long COVID, with funding from the U.S. Department of Defense.
The board includes four of the leading experts in long COVID, including Sherry Chou, MD and Igor Koralnik, MD, of Northwestern Medicine Neurology. Dr. Chou and Dr. Koralnik are experts in the neurological sequelae of COVID-19 and were the first to characterize the neurological complications in hospitalized COVID-19 patients in the U.S. Dr. Chou, who is the chief of Neurocritical Care and associate professor of Neurology at Northwestern Medicine, founded and leads the Global Consortium Study on Neurological Dysfunction in COVID-19 and serves as an invited member to the World Health Organization forum on neurological impacts of COVID-19. Dr Koralnik, chief of Neuro-infectious Disease and Global Neurology in the Department of Neurology at Northwestern Medicine, created one of the first neurological COVID-19 clinics in the country. Through this clinic, he and his team investigate, diagnose and manage neurological symptoms of long COVID. Read the full announcement > |
Igor Koralnik, MD is the Chief of Neuro-infectious Disease and Global Neurology in the Department of Neurology at Northwestern Medicine.
Sherry H-Y Chou, MD, Chief of Neurocritical Care and associate professor of Neurocritical Care at Northwestern Medicine.
Refer a PatientNorthwestern Medicine welcomes the opportunity to partner with you in caring for your patients.
|
You May Also Like
|
|
|